S
Sandra Muschiol
Researcher at Karolinska University Hospital
Publications - 42
Citations - 2809
Sandra Muschiol is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 13, co-authored 29 publications receiving 1716 citations. Previous affiliations of Sandra Muschiol include Karolinska Institutet & Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.
Takuya Sekine,André Perez-Potti,Olga Rivera-Ballesteros,Kristoffer Strålin,Jean Baptiste Gorin,Annika Olsson,Sian Llewellyn-Lacey,Habiba Kamal,Gordana Bogdanovic,Sandra Muschiol,David J. Wullimann,Tobias Kammann,Johanna Emgård,Tiphaine Parrot,Elin Folkesson,Olav Rooyackers,Lars Eriksson,Jan-Inge Henter,Anders Sönnerborg,Tobias Allander,Jan Albert,Morten Nielsen,Jonas Klingström,Sara Gredmark-Russ,Niklas K. Björkström,Johan K. Sandberg,David Price,Hans-Gustaf Ljunggren,Soo Aleman,Marcus Buggert +29 more
TL;DR: It is shown that SARS-CoV-2 elicits robust, broad and highly functional memory T cell responses, suggesting that natural exposure or infection may prevent recurrent episodes of severe COVID-19.
Posted ContentDOI
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
Takuya Sekine,André Perez-Potti,Olga Rivera-Ballesteros,Kristoffer Strålin,Jean-Baptiste Gorin,Annika Olsson,Sian Llewellyn-Lacey,Habiba Kamal,Gordana Bogdanovic,Sandra Muschiol,David J. Wullimann,Tobias Kammann,Johanna Emgård,Tiphaine Parrot,Elin Folkesson,Olav Rooyackers,Olav Rooyackers,Lars Eriksson,Lars Eriksson,Anders Sönnerborg,Tobias Allander,Tobias Allander,Jan Albert,Jan Albert,Morten Nielsen,Jonas Klingström,Sara Gredmark-Russ,Niklas K. Björkström,Johan K. Sandberg,David Price,Hans-Gustaf Ljunggren,Soo Aleman,Marcus Buggert +32 more
TL;DR: The collective dataset shows that SARS-CoV-2 elicits robust memory T cell responses akin to those observed in the context of successful vaccines, suggesting that natural exposure or infection may prevent recurrent episodes of severe COVID-19 also in seronegative individuals.
Journal ArticleDOI
A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis
Sandra Muschiol,Leslie Bailey,Åsa Gylfe,Charlotta Sundin,Kjell Hultenby,Sven Bergström,Mikael Elofsson,Hans Wolf-Watz,Staffan Normark,Birgitta Henriques-Normark +9 more
TL;DR: It is shown that one of these compounds, INP0400, inhibits intracellular replication and infectivity of C. trachomatis at micromolar concentrations resulting in small inclusion bodies frequently containing only one or a few reticulate bodies (RBs).
Journal ArticleDOI
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Peter Bergman,Peter Bergman,Ola Blennow,Ola Blennow,Lotta Hansson,Lotta Hansson,Stephan Mielke,Stephan Mielke,Piotr Nowak,Piotr Nowak,Piotr Nowak,Puran Chen,Gunnar Söderdahl,Gunnar Söderdahl,Anders Österborg,Anders Österborg,C. I. Edvard Smith,David J. Wullimann,Jan Vesterbacka,Gustaf Lindgren,Lisa Blixt,Lisa Blixt,Gustav Friman,Gustav Friman,Emilie Wahren Borgström,Anna Nordlander,Angelica Cuapio Gomez,Mira Akber,Davide Valentini,Anna-Carin Norlin,Anders Thalme,Gordana Bogdanovic,Sandra Muschiol,Sandra Muschiol,Peter Nilsson,Sophia Hober,Karin Loré,Margaret Chen,Marcus Buggert,Hans-Gustav Ljunggren,Per Ljungman,Per Ljungman,Soo Aleman,Soo Aleman +43 more
TL;DR: In this paper, the authors investigated safety and efficacy of BNT162b2 mRNA vaccination in five selected groups of immunocompromised patients and healthy controls and found that the vaccine was safe.
Journal ArticleDOI
Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle.
Leslie Bailey,Åsa Gylfe,Charlotta Sundin,Sandra Muschiol,Mikael Elofsson,Peter Nordström,Birgitta Henriques-Normark,Raimond Lugert,Anders Waldenström,Hans Wolf-Watz,Sven Bergström +10 more
TL;DR: Small molecules of a chemical class of acylated hydrazones of salicylaldehydes that specifically blocks the T3SS of Chlamydia are identified and suggest a previously unexplored avenue for development of novel anti‐chlamydial drugs.